Evaxion A (EVAX) Shares Outstanding (Weighted Average) (2019 - 2026)
Evaxion A posted quarterly Shares Outstanding (Weighted Average) of $16.0 billion for Q1 2026, down 94.19% year-on-year from $276.3 billion in Q1 2025, and up 1.58% on a QoQ basis from $15.8 billion in Q4 2025.
Evaxion A (EVAX) has 8 years of Shares Outstanding (Weighted Average) data on file, last reported at $16.0 billion in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) fell 94.19% year-over-year to $16.0 billion; the trailing twelve-month figure through Mar 2026 stood at $16.0 billion (down 94.19% YoY), and the FY2025 full-year result was $417.0 million, up 677.36% from the prior year.
- Shares Outstanding (Weighted Average) for Q1 2026 stood at $16.0 billion, up from $15.8 billion in the prior quarter.
- Across five years, Shares Outstanding (Weighted Average) topped out at $276.3 billion in Q1 2025 and bottomed at $30.0 in Q1 2024.
- The 5-year median for Shares Outstanding (Weighted Average) is $3.9 billion (2022), against an average of $23.6 billion.
- The widest annual swing landed in 2024, when Shares Outstanding (Weighted Average) slumped 100.0%; it then soared 921039756566.67% in 2025.
- A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $23.6 million in 2022, then surged by 60.32% to $37.9 million in 2023, then soared by 41.55% to $53.6 million in 2024, then surged by 29336.39% to $15.8 billion in 2025, then rose by 1.58% to $16.0 billion in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $16.0 billion (Q1 2026), $15.8 billion (Q4 2025), and $13.8 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 16.04 Bn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 132.89 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 198.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.04 Bn |
| Dec 31, 2025 | 15.79 Bn |
| Sep 30, 2025 | 13.81 Bn |
| Jun 30, 2025 | 11.82 Bn |
| Mar 31, 2025 | 276.31 Bn |
| Dec 31, 2024 | 53.64 Mn |
| Sep 30, 2024 | 55.26 Bn |
| Jun 30, 2024 | 120.00 |
| Mar 31, 2024 | 30.00 |
| Dec 31, 2023 | 37.90 Mn |
| Sep 30, 2023 | 4.42 Bn |
| Jun 30, 2023 | 460.00 |
| Mar 31, 2023 | 4.22 Bn |
| Dec 31, 2022 | 23.64 Mn |
| Sep 30, 2022 | 3.86 Bn |
| Jun 30, 2022 | 450.00 |
| Mar 31, 2022 | 250.00 |
| Dec 31, 2021 | 23.20 Mn |
| Sep 30, 2021 | 860.00 |
| Jun 30, 2021 | 3.13 Bn |
| Mar 31, 2021 | 230.00 |
| Dec 31, 2020 | 15.43 Mn |
| Sep 30, 2020 | 710.00 |
| Jun 30, 2020 | 440.00 |
| Mar 31, 2020 | 200.00 |
| Dec 31, 2019 | 13.89 Mn |